Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | PKLR | P30613 | 5/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | FABP1 | P07148 | 1/20 | 0.62 |
| ▸ | MMP2 | P08253 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30708093 | 1.00 | ALDH1A1 (0.76) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL3555597 | 0.91 | FABP1 (0.74) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL15713614 | 0.88 | ALDH1A1 (0.72) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL18753536 | 0.88 | ALDH1A1 (0.78) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL15480551 | 0.87 | MEN1 (0.73) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL17210223 | 0.86 | ALDH1A1 (1.00) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL16051474 | 0.86 | PKLR (0.58) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL808364 | 0.85 | ALDH1A1 (1.00) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL3556516 | 0.84 | ALDH1A1 (0.60) | ALDH1A1GAAMEN1KMT2ATP53 | |
| SCHEMBL16051590 | 0.84 | GAA (0.67) | ALDH1A1GAAMEN1KMT2APKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612381-B2 | Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | AGIOS PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12428376-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240360083-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2024-10-31 | — | — | US | disclosed |
| CN-117551030-A | Crystalline forms of N- (4- (4- (cyclopropylmethyl) piperazine-1-carbonyl) phenyl) quinoline-8-sulfonamide | 安吉奥斯医药品有限公司 | 2024-02-13 | — | — | CN | disclosed |
| US-11866411-B2 | Therapeutic compounds and compositions | Agios Pharmaceutical, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-4285904-A2 | CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE | Agios Pharmaceuticals, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-111372920-B | Crystalline forms of N- (4- (4- (cyclopropylmethyl) piperazine-1-carbonyl) phenyl) quinoline-8-sulfonamide | 安吉奥斯医药品有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-3713919-B1 | CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE | AGIOS PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3713919-B1 | CRYSTALLINE FORMS OF N-(4-(4-(CYCLOPROPYLMETHYL) PIPERAZINE-1-CARBONYL)PHENYL)QUINOLINE-8-SULFONAMIDE | AGIOS PHARMACEUTICALS INC (US) | 2023-08-02 | — | — | EP | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| EP-2448582-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | Agios Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002817-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002817-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-6251917-B1 | Benzamidoaldehydes and their use as cysteine protease inhibitors | BASF AKTIENGESELLSCHAFT (DE) | 2001-06-26 | — | — | US | disclosed |
| CN-1238761-A | benzamide aldehydes and their use as cysteine protease inhibitors | BASF AG (DE) | 1999-12-15 | — | — | CN | disclosed |
| EP-0944584-A1 | BENZAMIDOALDEHYDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1999-09-29 | — | — | EP | disclosed |
| WO-1998023581-A1 | BENZAMIDOALDEHYDES AND THEIR USE AS CYSTEINE PROTEASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428376-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885GAA 1253/4885MEN1 3010/4885 |
| US-20240360083-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885GAA 1253/4885MEN1 3010/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885GAA 1253/4885MEN1 3010/4885 |
| US-12612381-B2 | Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | PKLR, PKM, HBZ | ALDH1A1 2830/4885GAA 128/4885MEN1 4867/4885 |
| US-11866411-B2 | Therapeutic compounds and compositions | PDK1, PDK2, PDK3 | ALDH1A1 1326/4885GAA 1253/4885MEN1 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.